Evaluation of intravenous flavopiridol formulations.
Flavopiridol is currently under consideration as a parenteral treatment of breast tumors. The solubility of this poorly water-soluble compound can be increased by a number of methods. However, because of its low water solubility, precipitation of the solubilized drug upon injection can be a problem. The potential of several flavopiridol formulations to precipitate is evaluated using a static serial dilution technique. It is shown that formulations containing up to 10 mg/mL of flavopiridol which produce negligible precipitation on dilution can be developed.